GlobeNewswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:00:00时区推断·⟳ 抓取 20:02:18·⚡ 决策 07-30 20:08:35 +6m17s·88.9 天前
Intellia将于8月6日召开二季度财报电话会
公告仅通知2026年8月6日8:00 ET召开二季度财报和业务更新电话会，未披露临床、财务或监管增量。
📄 原文GlobeNewswire Biotechnology↗ 原文
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceut…
不做 Intellia Therapeutics（NTLA.US）
财报和业务更新电话会日程本身没有新增基本面信息，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 low ↗
消息传播链
- 公司宣布将于2026年8月6日召开二季度财报和业务更新电话会。
关键理由
- 公告仅通知2026年8月6日8:00 ET召开二季度财报和业务更新电话会，未披露临床、财务或监管增量。
主要风险
- 临近业务更新可能带来波动，但日程公告本身不构成交易催化。
工具调用 · 历史记录,结果未知(2 种)
- normalize_ticker · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,702 字
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.
To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
A replay of the call will be available for approximately 90 days on the Events page in the Investors & Media section of Intellia’s website, www.intelliatx.com.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com
To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
A replay of the call will be available for approximately 90 days on the Events page in the Investors & Media section of Intellia’s website, www.intelliatx.com.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。